This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-09 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
== Potential risks == In December 2024, 38 scientists, including several synthetic biology researchers and two Nobel laureates, warned that the creation of mirror-image life could cause "unprecedented and irreversible harm" to human health and ecosystems worldwide. The reversed structure of mirror-image bacteria could allow them to evade many mechanisms critical for immunity and predation that have evolved to recognize natural-chirality structures. As a result, mirror-image bacteria could potentially escape immune defenses and invade natural ecosystems, leading to "pervasive lethal infections in a substantial fraction of plant and animal species, including humans." Given these risks, the scientists concluded that mirror-image organisms should not be created without compelling evidence of safety. As of January 2026, no researchers are known to be pursuing the creation of mirror life; several who had been pursuing it have since renounced it and signed on as coauthors on the 2024 paper. Since the publication of the 2024 paper, 96 biotechnology experts signed a statement agreeing with its conclusions, and attendees of the first international conference on mirror-image life largely agreed that it should not be created. Germany’s Central Commission for Biological Safety (ZKBS) issued a statement that while applied research on mirror biomolecules should continue, mirror bacteria could pose serious risks, and that "a broad scientific and societal debate" was necessary.
In October 2004 the National Agency for Urban Renewal (ANRU) signed with the municipality of Havre the first agreement to finance the rehabilitation of these areas. This finance agreement provides more than 340 million euros for the housing estates in the northern districts, where about 41,000 people reside. This development extends the budget for the Grand Projet de Ville (GPV). It allows the demolition and rebuilding of more than 1,700 homes.
For example, the construction of multi-micron structures into larger architectures was accomplished using “criss-cross” polymerization. In this case, the additive components are “slats” instead of bricks. These slats have binding domains that allow them to attach perpendicularly to form a cross-linked structure. This approach stabilizes the structure, allowing for larger, highly ordered structures to form. This concept further reinforces the concept of smaller DNA components used as Legos to create larger structures without a bottom-up design. This approach also contrasts with earlier DNA origami techniques which relied on intricate computer software to design the scaffold and staple strands to enable creation of larger DNA nanostructures.
Sources: en.wikipedia.org
A gastric chief cell, peptic cell, or gastric zymogenic cell is a type of gastric gland cell that releases pepsinogen and gastric lipase. It is the cell responsible for secretion of chymosin (rennin) in ruminant animals and some other animals. The cell stains basophilic upon H&E staining due to the large proportion of rough endoplasmic reticulum in its cytoplasm. Gastric chief cells are generally located deep in the mucosal layer of the stomach lining, in the fundus and body of the stomach. Chief cells release the zymogen (enzyme precursor) pepsinogen when stimulated by a variety of factors including cholinergic activity from the vagus nerve and acidic condition in the stomach. Gastrin and secretin may also act as secretagogues. It works in conjunction with the parietal cell, which releases gastric acid, converting the pepsinogen into pepsin.
== Early career and provincial forestry == Recruited into the Imperial Forest Service during the early 1930s through a competitive, merit-based process, Singh began his career as a forest officer in the Bombay Presidency. He subsequently undertook provincial assignments in regions such as Punjab, where he managed resources amid challenges like habitat loss and poaching. He focused on combating overexploitation through regulated hunting, enhanced patrol systems, and community engagement. In 1957, he detailed his strategies for wildlife preservation and sustained timber yields in an article published in The Indian Forester. For his service in forest administration prior to Indian independence, the British Government appointed him a Member of the Order of the British Empire (MBE). On May 1, 1960, Singh was appointed Chief Conservator of Forests for Gujarat State, where he prioritized administrative efficiency and insulated operations from ad hoc political directives during a period of post-independence consolidation.
=== 24-norursodeoxycholic acid === A recent scientific breakthrough for cholestasis that has allowed us to evaluate a new treatment option is that a hydrophilic environment and bicarbonate production protects hepatocytes from bile acid. The novel agent norUDCA (24-norursodeoxycholic acid) can be passively absorbed by cholangiocytes. This leads to bicarbonate production and an environment that is less toxic. Mouse models have found promising results with norUDCA with the drug showing antiproliferative and anti-inflammatory properties. A recent clinical trial found norUDCA had significant dose-dependent reductions for ALP levels. This makes norUDCA a viable possibility to look into as it clearly plays a significant role in the treatment of cholestasis.
Sources: en.wikipedia.org
12 November – Downing Street confirms that Sue Gray will not take up a role as the prime minister's envoy to the nations and regions. The government sends a contingency of 470 delegates to the COP29 climate summit in Azerbaijan, with an estimated carbon dioxide footprint of at least 338 tons. The delegation is reported to comprise 354 government officials or ministers and 116 others including representatives from British overseas territories and crown dependencies, journalists, business figures and policy experts. By comparison, Italy sends 437, the US 405 and France 115. Starmer tells the COP29 climate conference that the UK will aim to reduce its emissions by 8% by 2035. Stephen Flynn, the SNP's leader at Westminster, announces his intention to stand at the 2026 Scottish Parliament election. Former Welsh government legal advisor Mick Antoniw and ex-minister Julie Morgan tell BBC News that subject to being passed at Westminster, the Terminally Ill Adults (End of Life) Bill would require a vote in the Senedd to become legal in Wales. 13 November – Health Secretary Wes Streeting orders a review into the potential cost to the NHS of implementing changes to the law regarding assisted dying. A report published by the Electoral Commission reveals that over half the 2024 general election candidates faced some kind of abuse. 14 November – Chancellor Rachel Reeves is reported to be planning the "biggest pension reform in decades" by merging council pension schemes into "pension megafunds" hoping they will boost economic growth.
=== Cases of poisoning === Despite the element's highly hazardous properties, circumstances in which polonium poisoning can occur are rare. Its extreme scarcity in nature, the short half-lives of all its isotopes, the specialised facilities and equipment needed to obtain any significant quantity, and safety precautions against laboratory accidents all make harmful exposure events unlikely. As such, only a handful of cases of radiation poisoning specifically attributable to polonium exposure have been confirmed.
2003: Researchers engineer an artemisinin precursor pathway in E. coli. 2004: First international conference for synthetic biology, Synthetic Biology 1.0 (SB1.0) is held at MIT. 2005: Researchers develop a light-sensing circuit in E. coli. Another group designs circuits capable of multicellular pattern formation. 2006: Researchers engineer a synthetic circuit that promotes bacterial invasion of tumour cells. 2010: Researchers publish in Science the first synthetic bacterial genome, called M. mycoides JCVI-syn1.0. The genome is made from chemically-synthesized DNA using yeast recombination. 2011: Functional synthetic chromosome arms are engineered in yeast. 2012: Charpentier and Doudna labs publish in Science the programming of CRISPR-Cas9 bacterial immunity for targeting DNA cleavage. This technology greatly simplified and expanded eukaryotic gene editing. 2019: Scientists at ETH Zurich report the creation of the first bacterial genome, named Caulobacter ethensis-2.0, made entirely by a computer, although a related viable form of C. ethensis-2.0 does not yet exist. 2019: Researchers report the production of a new synthetic (possibly artificial) form of viable life, a variant of the bacteria Escherichia coli, by reducing the natural number of 64 codons in the bacterial genome to 59 codons instead, in order to encode 20 amino acids. 2020: Scientists created the first xenobot, a programmable synthetic organism derived from frog cells and designed by AI. Demis Hassabis and John M. Jumper presented an AI model called AlphaFold2.
Peter Burke (born 1937) historian, professor and author of over twenty scholarly academic texts and monographs on European history, epistemology, ontology, prisms and perspectives on historiography and ideology; born to Roman Catholic father and Jewish mother (who later converted to Roman Catholicism); was member of School of European Studies at University of Sussex, before moving to University of Cambridge, where he holds title of Professor Emeritus of Cultural History and Fellow of Emmanuel College, Cambridge; celebrated as historian not only of early modern era, but one who emphasises relevance of social and cultural history to modern issues; in 1998, was awarded the Erasmus Medal of the European Academy, and is an honorary doctorate from the Universities of Lund, Copenhagen and Bucharest. Elias Canetti novelist, man of letters, 1981 Nobel Prize (Bulgarian-born); most famous for his work on mass psychology of crowds and anti-fascism, Crowds and Power David Cesarani (13 November 1956 – 25 October 2015) British historian who specialised in Jewish history, especially the Holocaust. He also wrote several biographies, including Arthur Koestler: The Homeless Mind (1998).
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.